Skip to content

Effects of temporary discontinuation of antihypertensive treatment in older patients with cognitive impairment: a randomised controlled trial. The DANTE Study Leiden, Discontinuation of ANtihypertensive Treatment in the Elderly

Effects of temporary discontinuation of antihypertensive treatment in older patients with cognitive impairment: a randomised controlled trial. The DANTE Study Leiden, Discontinuation of ANtihypertensive Treatment in the Elderly - DANTE study Leiden.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON37958
Enrollment
400
Registered
2010-12-17
Start date
2011-05-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressie, apathie, dagelijks functioneren en kwaliteit van leven Blood pressure and cognition

Interventions

Patients will be randomized to either continuation (n=200) or discontinuation (n=200) of antihypertensive treatment. Discontinuation of antihypertensive medication by patients* own general practitio

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) age >= 75 years, (2) current antihypertensive treatment with a calcium antagonist, beta-blocker, diuretic, ACE-inhibitor, or angiotensin-II-receptor blocker prescribed by their general practitioner for hypertension, (3) a last systolic blood pressure as reported in the chart of the general practitioner

Exclusion criteria

Exclusion criteria: A history of myocardial infarction and/or coronary reperfusion procedures (CABG/PCI)

Design outcomes

Primary

MeasureTime frame
Primary outcome is the change in the compound cognitive score between baseline and follow-up at 4 months after randomisation.

Secondary

MeasureTime frame
Secondary outcomes are the changes in the four separate cognitive domains (executive functioning, cognitive speed, immediate memory, and delayed memory); depressive symptoms, apathy, daily functioning, and quality of life between baseline and follow-up, 4 months after randomisation; and change in cerebral perfusion at MRI scan.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)